PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology

Executive Summary

• The Canadian Patent Office allowed PreveCeutical Medical Inc.’s patent application No. 3127020 (“A Cyclic Peptide”), a key component of its pain‑therapy program.
• The granted patent will provide exclusivity in Canada until January 2040 (subject to maintenance) and is part of a broader global family with pending applications in the U.S., Europe, and Australia.
• The approval underscores the company’s progress toward commercializing next‑generation peptide‑based analgesics that aim to reduce opioid‑related adverse effects.

Key Details

• Patent Application: Canadian Patent Application No. 3127020 titled “A Cyclic Peptide.”
• Technology Scope: Novel cyclized peptides that are analogues of dynorphin, intended for pain relief with reduced dependence, tolerance, and other opioid side‑effects. Includes pharmaceutical compositions and methods of use.
• Ownership: Jointly owned by PreveCeutical Medical Inc. and The University of Queensland.
• Exclusivity Period: Expected grant in Q2 2026; exclusivity in Canada through January 2040, subject to maintenance fees.
• Global Strategy: Corresponding patent applications pending in the United States, Europe, and Australia, forming a robust international IP portfolio.
• Program Focus: Development of peptide‑based analgesics leveraging cyclization for enhanced stability and receptor selectivity, targeting acute and chronic pain management.
• CEO Comment: Stephen Van Deventer highlighted the milestone as reinforcing PreveCeutical’s position in the market for safer opioid alternatives and supporting its long‑term commercialization path.

Notable Quotes

“The approval of this application is a significant milestone for PreveCeutical, reaffirming our commitment to pioneering next‑generation solutions in pain management. This intellectual property bolsters our position in a global market demanding safer alternatives to opioids and supports our long‑term path to commercialization.” – Stephen Van Deventer, Chairman & CEO

Materiality Assessment: Non‑Material – Positive (the patent allowance is a positive development but does not, on its own, constitute material financial impact).